$2.00 Million in Sales Expected for Agile Therapeutics, Inc. (NASDAQ:AGRX) This Quarter

Brokerages expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to announce $2.00 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Agile Therapeutics’ earnings. The lowest sales estimate is $1.51 million and the highest is $2.80 million. The business is expected to report its next earnings results on Thursday, November 11th.

According to Zacks, analysts expect that Agile Therapeutics will report full year sales of $7.30 million for the current fiscal year, with estimates ranging from $5.22 million to $9.60 million. For the next fiscal year, analysts forecast that the business will post sales of $51.50 million, with estimates ranging from $28.15 million to $65.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Sunday, July 25th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.02. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.45 million.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $1.03 price target (down from $6.00) on shares of Agile Therapeutics in a research report on Tuesday, July 27th. Maxim Group restated a “buy” rating and issued a $4.00 price target on shares of Agile Therapeutics in a research report on Friday, August 20th. Finally, HC Wainwright reduced their price objective on shares of Agile Therapeutics from $7.00 to $3.50 and set a “buy” rating on the stock in a research note on Monday, September 13th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $3.63.

In other Agile Therapeutics news, CFO Dennis Reilly acquired 50,000 shares of the stock in a transaction on Tuesday, July 27th. The shares were purchased at an average price of $1.08 per share, for a total transaction of $54,000.00. Following the completion of the acquisition, the chief financial officer now owns 226,306 shares in the company, valued at approximately $244,410.48. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Alfred Altomari bought 26,200 shares of the stock in a transaction dated Thursday, July 29th. The stock was purchased at an average price of $1.26 per share, with a total value of $33,012.00. The disclosure for this purchase can be found here. Corporate insiders own 8.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in Agile Therapeutics during the first quarter worth about $291,000. Grimes & Company Inc. increased its holdings in Agile Therapeutics by 71.6% during the first quarter. Grimes & Company Inc. now owns 51,486 shares of the specialty pharmaceutical company’s stock worth $107,000 after buying an additional 21,486 shares during the last quarter. Geode Capital Management LLC increased its holdings in Agile Therapeutics by 12.2% during the first quarter. Geode Capital Management LLC now owns 1,237,241 shares of the specialty pharmaceutical company’s stock worth $2,573,000 after buying an additional 134,999 shares during the last quarter. M Holdings Securities Inc. purchased a new stake in Agile Therapeutics during the first quarter worth about $75,000. Finally, Renaissance Technologies LLC purchased a new stake in Agile Therapeutics during the first quarter worth about $798,000. Institutional investors own 36.84% of the company’s stock.

NASDAQ AGRX traded down $0.07 on Monday, hitting $1.01. The company’s stock had a trading volume of 686,597 shares, compared to its average volume of 1,160,263. The company has a quick ratio of 2.88, a current ratio of 3.18 and a debt-to-equity ratio of 0.65. Agile Therapeutics has a 1-year low of $0.93 and a 1-year high of $3.84. The company’s 50-day moving average is $1.13 and its 200 day moving average is $1.51. The firm has a market cap of $93.93 million, a PE ratio of -1.29 and a beta of 0.95.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Read More: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.